Lustig RH, Rose SR, Burghen GA, Velasquez-Mieyer P, Broome DC, Smith K, et al
Current NHS guidance (at the time of writing) states that Semaglutide (Wegovy) can be prescribed for obesity for a maximum of two years
The substance had a short life but scientists modified it for use in humans to allow patients to produce more insulin as they needed it
That kind of research is less conclusive than clinical trials that follow subjects over time to create new and theoretically more reliable data that can do more to prove cause and effect
Here is a summary of the most solidly established effects: Improved skin firmness: Several controlled clinical studies have demonstrated a measurable increase in skin firmness after 8 to 12 weeks of topical application of creams containing GHK-Cu
Visceral fat is stored in the abdominal cavity, wrapped around internal organs